Metabasis Therapeutics Expands Leadership Team to Advance Internal Drug Candidates

Metabasis Therapeutics, Inc., a biopharmaceutical company, has strengthened its leadership team with the appointment of Howard Foyt, MD, PhD as vice president, clinical development; R. Wayne Frost, PharmD, JD as vice president, regulatory affairs and quality assurance; and Jeff Jensen as senior director, clinical operations. These additions demonstrate Metabasis' commitment to advancing its internally discovered proprietary drug candidates in human clinical studies.

The company currently has three product candidates in clinical development and expects two additional product candidates to begin human clinical trials over the next 3-to-9 months. The new hires bring a wealth of experience in their respective fields, with Foyt joining from Pfizer Global Research & Development after 10 years of industry experience, Frost bringing over 20 years of experience in regulatory affairs, and Jensen bringing over 25 years of clinical operations experience.

Key Takeaways:

Metabasis Therapeutics has appointed three new executives to its leadership team: Howard Foyt, MD, PhD, R. Wayne Frost, PharmD, JD, and Jeff Jensen.
The company has three product candidates in clinical development and expects two additional product candidates to begin human clinical trials in the next 3-to-9 months.
Foyt joins from Pfizer Global Research & Development, where he served as senior director, medical and development sciences and therapy area site head - diabetes obesity obesity, after 10 years in the industry.
Frost has over 20 years of experience in the pharmaceutical industry, with 15 years in regulatory affairs, and has held positions at Amgen Inc. and Pfizer Global Research and Development.
Jensen brings over 25 years of clinical operations experience to Metabasis, having previously worked at Pfizer and clinical research organizations such as INC Research, Inc. and Quintiles, Inc.

Statistics:

Average industry experience of the new hires: 20.3 years
Number of product candidates in clinical development: 3
Number of product candidates expected to begin human clinical trials in the next 3-to-9 months: 2
Industry experience of Howard Foyt, MD, PhD: 10 years
Industry experience of R. Wayne Frost, PharmD, JD: 20 years
Industry experience of Jeff Jensen: 25 years

Sources:

Health & Medicine Week editors
NewsRx.com